Clinical Corner
Trials & Updates
Clinical Trial Highlight: Refractory Cancers
This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with refractory malignancies.
Questions about how to send a patient? Please contact the Clinical Trials Office at cancer-center@ufl.edu
or 352.273.8675
This open-label, single arm study is investigating the use of niraparib (an oral PARP inhibitor) in patients with tumors known to have mutations in BAP1 and a variety of other DNA damage response pathway genes. The primary aim is to determine the objective response rate of patients with BAP1 and other DDR repair pathway deficiencies. Cohorts include the histologies above (regardless of mutation) as well as any tumor histology with a confirmed DDR repair pathway mutation.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672
This is an investigator-initiated clinical trial that is based on the discovery of the importance of the Metnase complex in repairing chemotherapy-related DNA damage in leukemia. Ciprofloxacin has been identified as a metnase inhibitor that chemosensitizes leukemic myeloblasts to etoposide chemotherapy. The primary aims are to determine the maximum tolerated dose of ciprofloxacin that can be given in combination with a fixed dose of etoposide and determine the efficacy of the combination treatment in adults with resistant AML.
Principal Investigator: Randy Brown, M.D., cell: 859.221.6828
Phase II Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
This open-label Phase 2 study tests tisotumab vedotin (an antibody-drug conjugate targeting tissue factor expressed by refractory solid tumors) in patients with metastatic lung, head and neck, pancreatic and colorectal cancers.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672
Prostate Cancer Awareness Month Efforts
One in nine men will be diagnosed with prostate cancer in their lifetime. This disease is the second most common cancer and the second leading cause of cancer deaths for men in the United States. To bring awareness to this event, the Cancer Center and its members engaged in the following efforts this month:
Awareness Event
In recognition of Prostate Cancer Awareness Month, University of Florida Health hosted a prostate cancer awareness event to share new prostate screening recommendations, MRI-targeted prostate biopsy options and the latest treatment options with the public. Activities included a prostate biopsy dart board game and demonstrations of the da Vinci™ robotic surgical system. Participants also took photo with a photo frame and learned about ways to prevent prostate cancer.
The event was on Tuesday, Sept. 4 from 9 a.m. to noon in the UF Health Shands Hospital Atrium. The following prostate cancer experts attended:
- Li-Ming Su, M.D., chair, department of urology
- Joseph R. Grajo, M.D., assistant professor, chief of abdominial imaging
- Thomas F. Stringer, M.D., assistant professor, associate chair, department of urology
- Brandon Otto, M.D., assistant professor, department of urology
Social Media
Blog Post: “Six Things You Should Know About Prostate Cancer” featuring Thomas Stringer, M.D.
Video: UF Health urologists Brandon Otto, M.D., and Thomas Stringer, M.D., answer the most common questions about prostate cancer — and quickly review what you need to know about screening for this disease.
Media Coverage
Citrus County Chronicle: “Prostate Cancer Treatment Makes Big Strides” featuring Dr. Thomas Stringer
TV-20: UF Health hosts “Prostate Cancer Awareness Month” event
Marketing
Problem-Solving Specialty Care at UF Health | Dr. Sem Lampotang’s story of Prostate Cancer
Dr. Sem Lampotang’s cancer was discovered by using a new technology to target the tumor. Learn how a UF Health problem-solver in urologic oncology diagnosed Sem’s cancer and gave him a second chance. Click here for the full story.